US2017320818A1PendingUtilityA1

Sulfamoylbenzamide derivatives as antiviral agents against hbv infection

Assignee: UNIV DREXELPriority: Jul 1, 2011Filed: Jul 21, 2017Published: Nov 9, 2017
Est. expiryJul 1, 2031(~4.9 yrs left)· nominal 20-yr term from priority
A61P 31/14A61P 43/00A61P 31/20A61K 31/167A61K 31/54A61K 31/4453A61K 31/553A61K 2300/00C07D 281/16C07D 307/68C07D 213/40A61K 31/5375A61K 31/554A61K 31/5377A61K 31/4406C07D 223/04C07C 311/46C07D 295/26A61K 31/55A61K 31/18C07D 211/96A61K 31/44C07D 307/52C07C 311/16A61K 31/341C07D 281/14A61K 31/541A61K 31/445C07D 213/42
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound of formula (I): 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  is H; 
 R 2  is selected from the group consisting of H, CH 3 , CF 3 , F and Cl; 
 R 3  is selected from the group consisting of H, CH 3 , F and Cl; 
 R 4  is selected from the group consisting of H, F, Cl and CH 3 ; 
 R 5  is selected from the group consisting of H and Cl; 
 R 7  is selected from the group consisting of H, Cl, F and Br; 
 R 9  is selected from the group consisting of H, CH 3 , F and Cl; 
 R x  is selected from the group consisting of: 
 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the at least one compound is selected from the group consisting of:
 2-Chloro-5-sulfamoyl-N-3-methylphenyl-benzamide;   4-Fluoro-3-sulfamoyl-N-(3-trifluoromethyl-phenyl)-benzamide;   N-(2-Chloro-5-trifluoromethyl-phenyl)-4-fluoro-3-sulfamoyl-benzamide;   N-Phenyl-3-sulfamoyl-benzamide;   5-sec-Butylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   3-Diethylsulfamoyl-N-phenyl-benzamide;   5-Diethylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   2-Chloro-5-diethylsulfamoyl-N-m-tolyl-benzamide;   N-(4-Chloro-phenyl)-3-diethylsulfamoyl-benzamide;   5-Allylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   N-(3,4-Difluoro-phenyl)-5-dipropylsulfamoyl-2-fluoro-benzamide;   5-Cycloheptylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   5-Cycloheptylsulfamoyl-2-fluoro-N-p-tolyl-benzamide;   5-Cyclohexylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   2-Bromo-5-cyclohexylsulfamoyl-N-phenyl-benzamide;   4-Chloro-3-cyclohexylsulfamoyl-N-(4-fluoro-phenyl)-benzamide;   3-Cyclohexylsulfamoyl-4-methyl-N-phenyl-benzamide;   N-(3,4-Difluoro-phenyl)-4-fluoro-3-(2-methyl-cyclohexylsulfamoyl)-benzamide;   3-Cyclopentylsulfamoyl-N-phenyl-benzamide;   5-Cyclopentylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   5-Cyclopentylsulfamoyl-2-fluoro-N-(4-fluoro-phenyl)-benzamide;   5-Cyclopentylsulfamoyl-N-(3,5-dimethyl-phenyl)-2-fluoro-benzamide;   3-Cyclopentylsulfamoyl-4-fluoro-N-3-methylphenyl-benzamide;   5-Cyclopentylsulfamoyl-N-(3,5-dichloro-phenyl)-2-fluoro-benzamide;   3-[(Furan-2-ylmethyl)-sulfamoyl]-N-phenyl-benzamide;   N-(3-Chloro-4-fluoro-phenyl)-5-[(furan-2-ylmethyl)-sulfamoyl]-2-methyl-benzamide;   2-Fluoro-N-(3-fluoro-phenyl)-5-[(furan-2-ylmethyl)-sulfamoyl]-benzamide;   N-(3,5-Dichloro-phenyl)-2-fluoro-5-[(furan-2-ylmethyl)-sulfamoyl]-benzamide;   4-Fluoro-3-[(furan-2-ylmethyl)-sulfamoyl]-N-3-methylphenyl-benzamide;   5-[(4-Chloro-3-phenylcarbamoyl-benzenesulfonylamino)-methyl]-furan-2-carboxylic acid methyl ester;   N-(3-Chloro-phenyl)-5-(2-cyclohex-1-enyl-ethylsulfamoyl)-2-fluoro-benzamide;   5-(2-Cyclohex-1-enyl-ethylsulfamoyl)-N-(3,5-dimethyl-phenyl)-2-fluoro-benzamide;   5-(2-Cyclohex-1-enyl-ethylsulfamoyl)-N-(3,5-dimethyl-phenyl)-2-fluoro-benzamide;   N-(3-Chloro-phenyl)-4-fluoro-3-[(pyridin-3-ylmethyl)-sulfamoyl]-benzamide;   N-(3,4-Difluoro-phenyl)-2-fluoro-5-phenethylsulfamoyl-benzamide;   N-(3-Chloro-phenyl)-2-fluoro-5-phenethylsulfamoyl-benzamide;   5-Benzylsulfamoyl-N-(3-chloro-4-fluoro-phenyl)-2-fluoro-benzamide;   5-Benzylsulfamoyl-2-chloro-N-phenyl-benzamide;   N-(4-Chloro-phenyl)-5-[2-(3,4-dimethoxy-phenyl)-ethylsulfamoyl]-2-fluoro-benzamide;   5-(2-Chloro-benzylsulfamoyl)-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   3-(2-Chloro-benzylsulfamoyl)-N-(4-chloro-phenyl)-4-fluoro-benzamide;   2-Fluoro-5-(4-methoxy-phenylsulfamoyl)-N-3-methylphenyl-benzamide;   2-Fluoro-5-(4-fluoro-phenylsulfamoyl)-N-3-methylphenyl-benzamide;   N-(4-Chloro-phenyl)-3-(3-fluoro-phenylsulfamoyl)-benzamide;   N-(4-Chloro-phenyl)-3-2-methylphenylsulfamoyl-benzamide;   N-Phenyl-3-m-tolylsulfamoyl-benzamide;   N-Phenyl-3-o-tolylsulfamoyl-benzamide;   3-(Benzyl-ethyl-sulfamoyl)-N-(3,4-difluoro-phenyl)-4-fluoro-benzamide;   5-(Azepane-1-sulfonyl)-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   4-Methyl-N-phenyl-3-(piperidine-1-sulfonyl)-benzamide;   4-Methyl-N-phenyl-3-(piperidine-1-sulfonyl)-benzamide;   4-Chloro-N-(3-fluoro-phenyl)-3-(morpholine-4-sulfonyl)-benzamide;   4-Chloro-N-phenyl-3-(thiomorpholine-4-sulfonyl)-benzamide;   any pharmaceutically acceptable salt thereof, and any mixtures thereof.   
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the compound of formula (I) is the compound of formula (II): 
       
         
           
           
               
               
           
         
       
       wherein:
 R x  is selected from the group consisting of: 
 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the at least one compound is selected from the group consisting of:
 5-sec-Butyl sulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   5-Diethyl sulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   5-Allylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   N-(3,4-Difluoro-phenyl)-5-dipropyl sulfamoyl-2-fluoro-benzamide;   5-Cycloheptylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   5-(Azepane-1-sulfonyl)-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   5-Cyclohexylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   5-Cyclopentylsulfamoyl-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   N-(3,4-Difluoro-phenyl)-2-fluoro-5-phenethylsulfamoyl-benzamide;   5-(2-Chloro-benzyl sulfamoyl)-N-(3,4-difluoro-phenyl)-2-fluoro-benzamide;   any pharmaceutically acceptable salt thereof, and any mixtures thereof.

Join the waitlist — get patent alerts

Track US2017320818A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.